Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
MENLO PARK, Calif., Nov. 07, 2016 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Stifel 2016 Healthcare Conference in New York at 9:30 a.m. ET on Tuesday, November 15, 2016.
- Piper Jaffray 28th Annual Healthcare Conference in New York at 12:30 p.m. ET on Wednesday, November 30, 2016.
A live audio webcast of each presentation will be available through the Homepage and Investor Relations section of Geron’s website under Events. Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
